United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 15.1% in the third quarter, Holdings Channel reports. The firm owned 21,565 shares of the biotechnology company’s stock after selling 3,841 shares during the period. Amalgamated Bank’s holdings in United Therapeutics were worth $7,728,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. ClariVest Asset Management LLC raised its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. USA Financial Formulas purchased a new position in United Therapeutics in the third quarter valued at about $33,000. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the second quarter worth about $33,000. Finally, Values First Advisors Inc. acquired a new stake in shares of United Therapeutics in the third quarter valued at about $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on UTHR shares. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Jefferies Financial Group upped their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $370.86.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of United Therapeutics stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $964,983.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, COO Michael Benkowitz sold 14,700 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $964,983.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,422 shares of company stock worth $29,229,828 over the last quarter. 11.90% of the stock is owned by company insiders.

United Therapeutics Trading Up 3.8 %

Shares of NASDAQ UTHR opened at $397.49 on Thursday. The company has a market capitalization of $17.75 billion, a price-to-earnings ratio of 17.46, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $399.23. The business has a 50 day simple moving average of $356.67 and a 200-day simple moving average of $319.83.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the firm earned $5.38 earnings per share. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Co. will post 25.57 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.